Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sutro Biopharma, Inc. (STRO : NSDQ)

• Company Description    Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. Number of Employees: 310

• Price / Volume Information    Yesterday's Closing Price: $9.83 Daily Weekly Monthly 20 Day Moving Average: 104,836 shares Shares Outstanding: 8.51 (millions) Market Capitalization: $83.69 (millions) Beta: 1.61 52 Week High: $22.30 52 Week Low: $5.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.81% 4.42% 12 Week 8.88% 5.77% Year To Date -46.58% -54.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 111 Oyster Point Blvd. - South San Francisco,CA 94080 USA ph: 650-881-6500 fax: - ewhite@sutrobio.com http://www.sutrobio.com

• General Corporate Information    Officers William J. Newell - President; Chief Executive Officer and Director Edward C. Albini - Chief Financial Officer and Corporate Secretary Michael Dybbs - Director John G. Freund - Director Heidi Hunter - Director Peer Information Sutro Biopharma, Inc. (CORR.) Sutro Biopharma, Inc. (RSPI) Sutro Biopharma, Inc. (CGXP) Sutro Biopharma, Inc. (BGEN) Sutro Biopharma, Inc. (GTBP) Sutro Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 869367201 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 8.51 Most Recent Split Date: 12.00 (0.10:1) Beta: 1.61 Market Capitalization: $83.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-4.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-20.94 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 34.79% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.80 EPS Growth vs. Year Ago Period: -13.56% vs. Previous Quarter: -378.57% Sales Growth vs. Year Ago Period: 13.77% vs. Previous Quarter: -84.79% ROE 09/30/25 - - 06/30/25 - -852.70 03/31/25 - -347.60 ROA 09/30/25 - -73.44 06/30/25 - -58.67 03/31/25 - -59.46 Current Ratio 09/30/25 - 2.53 06/30/25 - 3.12 03/31/25 - 2.16 Quick Ratio 09/30/25 - 2.53 06/30/25 - 3.12 03/31/25 - 2.16 Operating Margin 09/30/25 - -206.77 06/30/25 - -201.32 03/31/25 - -373.66 Net Margin 09/30/25 - -206.77 06/30/25 - -201.32 03/31/25 - -373.66 Pre-Tax Margin 09/30/25 - -204.54 06/30/25 - -199.07 03/31/25 - -370.06 Book Value 09/30/25 - -10.29 06/30/25 - -3.80 03/31/25 - -3.06 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©